# A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

> **NCT04679038** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 222 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** SHR-1701
- **DRUG:** Famitinib

## Key facts

- **NCT ID:** NCT04679038
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-17
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679038, "A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04679038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*